Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 11/20 | 0.60 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.60 |
| ▸ | CCR5 | P51681 | 1/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.56 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4513447 | 0.80 | KDM4E (0.54) | HDAC1GAAHPSEALOX15MAPK1 | |
| SCHEMBL1232960 | 0.78 | NR1H4 (0.71) | HDAC1CCR5PPARG | |
| SCHEMBL2380752 | 0.78 | HDAC1 (0.71) | HDAC1KCNMA1HDAC2GAAMAPK1 | |
| SCHEMBL5178629 | 0.77 | HDAC1 (0.69) | HDAC1KCNMA1HDAC2GAAMAPK1 | |
| SCHEMBL7817331 | 0.76 | HDAC1 (0.69) | HDAC1KCNMA1HDAC2GAA | |
| SCHEMBL13290711 | 0.76 | LMNA (0.64) | KCNMA1GAAPPARGALOX15MAPK1 | |
| SCHEMBL11247792 | 0.76 | KDM5A (0.55) | ALOX15MAPK1 | |
| SCHEMBL2639160 | 0.76 | FFAR1 (0.51) | CCR5GAAPPARG | |
| SCHEMBL12510751 | 0.76 | HDAC1 (0.67) | HDAC1KCNMA1HDAC2GAAMAPK1 | |
| SCHEMBL14476825 | 0.75 | KCNMA1 (1.00) | HDAC1KCNMA1HDAC2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318548-A1 | PARA-QUINOL DERIVATIVES AND METHODS OF STEREO SELECTIVELY SYNTHESIZING AND USING SAME | UNIVERSITY OF NORTHERN BRITISH COLUMBIA (CA) | 2009-12-24 | — | — | US | disclosed |
| US-20090318548-A1 | PARA-QUINOL DERIVATIVES AND METHODS OF STEREO SELECTIVELY SYNTHESIZING AND USING SAME | UNIVERSITY OF NORTHERN BRITISH COLUMBIA (CA) | 2009-12-24 | — | — | US | disclosed |
| WO-2008022462-A1 | PARA-QUINOL DERIVATIVES AND METHODS OF STEREO SELECTIVELY SYNTHESIZING AND USING SAME | UNIVERSITY OF NORTHERN BRITISH COLUMBIA (CA) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318548-A1 | PARA-QUINOL DERIVATIVES AND METHODS OF STEREO SELECTIVELY SYNTHESIZING AND USING SAME | CBR3, XDH, NQO2 | HDAC1 3374/4885KCNMA1 4191/4885CCR5 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.